Eva Marie Uzcategui | Bloomberg | Getty Images
The U.S. Food and Drug Administration has said it wants at least two months of safety data before authorizing emergency use of any experimental coronavirus vaccine.
Based on current trial enrollment and dosing pace, Pfizer expects to have that safety data in the third week of November, Chief Executive Officer Albert Bourla said in a statement.
Pfizer had said previously that it expected late-stage trial data in October.
This story is developing. Please check back for updates.